Abacavir

also known as ABC · abacavir sulfate · 1592U89 · abacavir succinate · Abacavir sulphate · ABC: abacavir: Ziagen · Ziagen

Other / unclassified

Developed for: HIV infectious disease · AIDS · lipodystrophy · amyotrophic lateral sclerosis · tuberculosis · HIV wasting syndrome · Aicardi-Goutieres syndrome · AIDS dementia complex
+4 more
· disease related to solid organ transplantation · lactic acidosis · systemic lupus erythematosus · Kaposi's sarcoma
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Glaxo Wellcome · ViiV Healthcare · GlaxoSmithKline · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Gilead Sciences
+84 more
· Germans Trias i Pujol Hospital · ANRS, Emerging Infectious Diseases · Fight AIDS and Infectious Diseases Foundation · Macquarie University, Australia · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Fundacion Clinic per a la Recerca Biomédica · Kirby Institute · National Institute of Mental Health (NIMH) · Pfizer · AMS-PHPT Research Platform (Program for HIV Prevention and Treatment) · Abbott · Assistance Publique - Hôpitaux de Paris · Baylor College of Medicine Children's Foundation · Bayside Health · Burroughs Wellcome · CIHR Canadian HIV Trials Network · Calvary Health Care Bethlehem · Catholic University of the Sacred Heart · Central Institute of Epidemiology, Moscow, Russia · Chulalongkorn University · Columbia University · David Garcia Cinca · Drugs for Neglected Diseases · Duke University · Dupont Applied Biosciences · Epcentre Centre Mbarara Research Centre · European and Developing Countries Clinical Trials Partnership (EDCTP) · French National Institute of Health and Medical Research · Fundacion SEIMC-GESIDA · Harvard School of Public Health (HSPH) · Hoffmann-La Roche · Hospices Civils de Lyon · Hospital de Granollers · Imperial College London · Institut de Sante Publique, d'Epidémiologie et de Développement · Institute of Tropical Medicine, Belgium · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Jan Gerstoft · Janssen Research & Development, LLC · Joint Clinical Research Centre- Kampala · Kibongoto National Tuberculosis Hospital, Tanzania · Kilimanjaro Christian Medical Centre, Tanzania · King's College London · Makerere University · Mater Misericordiae University Hospital · Merck Sharp & Dohme LLC · Mexican Social Security Institute · Ministry of Foreign Affairs, Luxembourg · Ministry of Health, Rwanda · Mylan Inc. · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes of Health (NIH) · Neuroscience Trials Australia · PENTA Foundation · PHPT/AMS Laboratory, Faculty of Associated Medical Sciences, Chiang Mai University · PPD Development, LP · Pharmaceutical Product Development, (PPD) LLC · Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire · Public Research Centre Health, Luxembourg · Queen Fabiola Children's University Hospital · Radboud University Medical Center · SEARCH Research Foundation · Shionogi · St Stephens Aids Trust · St Vincent's Hospital, Sydney · TRICALS Foundation · The HIV Netherlands Australia Thailand Research Collaboration · The University of New South Wales · Triangle Pharmaceuticals · Trimeris · UNITAID · URC-CIC Paris Descartes Necker Cochin · University College Dublin · University of Bordeaux · all 90 on the full record

Regulatory milestones approvals, filings & regulatory actions · 7 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (5)	US (FDA)	ZIAGEN	—	2000-12-15 – 2015-03-23	fda.gov ↗
Approved	EU (EMA)	Ziagen	—	1999-07-08	europa.eu ↗
Approved	US (FDA)	ZIAGEN	—	1998-12-17	fda.gov ↗

Trials 115 · started per year

today

US approved 1998

EU approved 1999

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05030025	Aug 2021	HIV infectious disease	Mylan Inc.	Completed	No outcome recorded
Phase 113 trials
Phase 1	NCT04827134	May → Jul 2021	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT03441984	Feb → Apr 2018	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT02539576	Oct → Nov 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT01366547	Jun → Jul 2011	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT01220232	Nov 2010 → Jan 2011	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT00320307	Sep 2005 → ?	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00001968	Jan → Nov 2000	AIDS	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002141	Jul 1994 → ?	HIV infectious disease	Burroughs Wellcome	Completed	No outcome recorded
Phase 1	NCT00011479	? → Aug 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00002183	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 1	NCT00002388	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 1	NCT00002198	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 1	NCT00000864	? → Jan 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT03760458	Sep 2020 → Dec 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT03836833	Jun → Nov 2019	HIV infectious disease	Drugs for Neglected Diseases	Unknown	No outcome recorded
Phase 224 trials
Phase 2	NCT06356740	Sep 2024 → Nov 2028 expected	systemic lupus erythematosus	Hospices Civils de Lyon	Not yet recruiting	No outcome recorded
Phase 2	NCT03602690	Oct 2018 → Apr 2022	HIV infectious disease	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
Phase 2	NCT02868580	Oct 2016 → Dec 2017	amyotrophic lateral sclerosis	Neuroscience Trials Australia	Completed	No outcome recorded
Phase 2	NCT02363452	Sep 2015 → Jan 2018	Aicardi-Goutieres syndrome	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT00958100	Aug 2009 → Nov 2010	AIDS	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 2	NCT00820118	May 2009 → May 2012	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT00270296	Jun 2006 → Mar 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00270556	Jan 2003 → Oct 2004	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00001132	Nov 1999 → Apr 2001	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000940	May 1999 → Oct 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002239	May 1999 → ?	HIV infectious disease	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT00001758	Nov 1997 → Aug 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00001086	? → Sep 1999	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002364	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00002213	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00102206	? → May 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002440	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00021463	? → Feb 2002	HIV infectious disease, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002390	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00000885	? → Jun 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00006152	? → Aug 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000872	? → Jan 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00002419	—	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00002233	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded

Phase 2/35 trials
Phase 2/3	NCT01656122	Jul 2012 → Jul 2015	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 2/3	NCT01127204	Jun 2011 → Apr 2015	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	No outcome recorded
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2/3	NCT00143702	Aug 2001 → Aug 2006	lactic acidosis	University of British Columbia	Completed	No outcome recorded
Phase 329 trials
Phase 3	NCT06658977	Nov 2024 → Jun 2025	amyotrophic lateral sclerosis	Macquarie University, Australia	Terminated	No outcome recorded
Phase 3	NCT05193994	Feb 2022 → Jun 2025	amyotrophic lateral sclerosis	Macquarie University, Australia	Terminated	No outcome recorded
Phase 3	NCT02588820	Apr 2016 → Nov 2018	HIV infectious disease	David Garcia Cinca	Unknown	No outcome recorded
Phase 3	NCT02075593	Dec 2014 → Oct 2018	HIV infectious disease, arthropathy	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT02105987	Apr 2014 → Apr 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT01910402	Aug 2013 → Sep 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT01352715	Mar 2012 → Oct 2014	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 3	NCT01440569	Sep 2011 → Aug 2012	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01153217	Jul 2010 → Jun 2012	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 3	NCT01146873	Jul 2010 → Dec 2014	AIDS	Columbia University	Completed	No outcome recorded
Phase 3	NCT00796263	May 2009 → Jun 2033 expected	HIV infectious disease	SEARCH Research Foundation	Recruiting	No outcome recorded
Phase 3	NCT00118898	Sep 2005 → Nov 2009	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 3	NCT00102960	Jul 2005 → Sep 2012	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00338390	Apr 2005 → Feb 2007	HIV infectious disease	Hospital de Granollers	Completed	No outcome recorded
Phase 3	NCT00314626	Nov 2004 → Feb 2007	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 3	NCT00078247	Oct 2004 → ?	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00094367	Jul 2004 → Oct 2005	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00086359	Jul 2004 → Sep 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00053638	Feb 2003 → Oct 2004	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00046176	Aug 2002 → May 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00044577	Jul 2002 → May 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00002362	Aug 1999 → ?	HIV infectious disease	Triangle Pharmaceuticals	Suspended	No outcome recorded
Phase 3	NCT00002245	Apr 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00006154	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002199	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00002391	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00013520	? → Jun 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00002163	—	AIDS dementia complex, HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00002389	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded

Phase 427 trials
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT06602622	Aug 2024 → Nov 2025 overdue	HIV wasting syndrome	Mexican Social Security Institute	Recruiting	No outcome recorded
Phase 4	NCT03360682	Apr 2018 → May 2020	HIV infectious disease, disease related to solid organ transplantation	Fundacion Clinic per a la Recerca Biomédica	Completed	No outcome recorded
Phase 4	NCT02659761	Nov 2016 → Sep 2021	HIV infectious disease	University College Dublin	Terminated	No outcome recorded
Phase 4	NCT02509195	Aug 2015 → Feb 2017	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 4	NCT02246998	Dec 2014 → Jan 2016	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT02093585	Jan 2014 → Apr 2016	HIV infectious disease	Jan Gerstoft	Completed	No outcome recorded
Phase 4	NCT01886638	Aug 2013 → Jun 2014	HIV infectious disease, cardiovascular disorder	Bayside Health	Completed	No outcome recorded
Phase 4	NCT01367236	Jan 2013 → Oct 2015	HIV infectious disease, cognitive disorder	Imperial College London	Completed	No outcome recorded
Phase 4	NCT01059422	Oct 2010 → Mar 2013	HIV infectious disease, tuberculosis	Central Institute of Epidemiology, Moscow, Russia	Completed	No outcome recorded
Phase 4	NCT01102972	Apr 2010 → Jun 2012	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00865475	Dec 2008 → Mar 2013	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT00335322	Feb 2007 → Mar 2011	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00337922	Jul 2006 → ?	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00340080	Apr 2006 → ?	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00356616	Sep 2005 → Jun 2007	HIV infectious disease	Germans Trias i Pujol Hospital	Terminated	No outcome recorded
Phase 4	NCT00244712	Jul 2005 → Apr 2008	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00335192	Jan → Sep 2005	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00851630	Jun 2004 → Sep 2007	HIV infectious disease, tuberculosis	Duke University	Completed	No outcome recorded
Phase 4	NCT00082394	Apr 2004 → Mar 2006	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00192660	Feb 2003 → Oct 2006	cardiovascular disorder, lipodystrophy	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00038506	Mar 2002 → Aug 2004	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00011895	Feb 2001 → ?	HIV infectious disease	GlaxoSmithKline	Unknown	No outcome recorded
Phase 4	NCT00005764	May 2000 → ?	HIV infectious disease, lipodystrophy	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00004585	Oct 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00005106	Sep 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 4	NCT00005018	Jul 1999 → Oct 2000	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded

Phase not applicable14 trials
—	NCT02384395	Sep 2015 → Mar 2020	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT00087945	Jul → Dec 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00028314	Mar 2002 → Mar 2005	HIV wasting syndrome, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00001119	Oct 1999 → Jun 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00000922	? → Jan 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002200	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002205	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00006578	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
—	NCT00000919	? → Nov 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00006617	? → Jun 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00004855	? → Apr 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002216	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002217	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
—	NCT00002197	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded

Also used as a comparator or background therapy in 68 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 18 trials
Phase 1	NCT06428045 Background	Apr 2025 → Apr 2029 expected	malignant glioma	University of Miami	Recruiting	No outcome recorded
Phase 1	NCT02556268 Background	Feb → Dec 2016	—	Bayer	Completed	No outcome recorded
Phase 1	NCT01052701 Comparator	Dec 2009 → Sep 2012	HIV infectious disease, hepatitis C virus infection	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT00765271 Comparator	May → Oct 2008	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 1	NCT01982396 Comparator	Jan 2003 → Feb 2004	HIV infectious disease	PENTA Foundation	Completed	No outcome recorded
Phase 1	NCT02182765 Comparator	Apr 1999 → Jul 2001	HIV infectious disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 1	NCT00001766 Background	Aug 1998 → Aug 2003	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000865 Background	? → Apr 1998	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 214 trials
Phase 2	NCT05729568 Background	May 2023 → Jul 2024 overdue	HIV infectious disease	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2	NCT04731103 Comparator	Aug 2022 → Mar 2024	Aicardi-Goutieres syndrome	University of Edinburgh	Completed	No outcome recorded
Phase 2	NCT04012931 Background	Jul 2019 → Feb 2023	HIV infectious disease	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT02120352 Comparator	Apr 2014 → Aug 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT01641809 Background	Aug 2012 → Oct 2013	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT00799864 Background	Jan 2011 → Aug 2022	—	Janssen Sciences Ireland UC	Completed	No outcome recorded
Phase 2	NCT00915655 Background	Jul 2009 → Sep 2010	HIV infectious disease	Tibotec Pharmaceuticals, Ireland	Completed	No outcome recorded
Phase 2	NCT00214890 Comparator	Dec 2004 → Jun 2008	HIV infectious disease	University of California, San Diego	Completed	No outcome recorded
Phase 2	NCT00084149 Background	Feb 2004 → Jan 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00647946 Comparator	Feb 2003 → Oct 2004	lipodystrophy	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00002423 Background	Mar 1999 → ?	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 2	NCT00031070 Background	? → Dec 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00000912 Background	? → May 2000	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00021489 Background	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT02016924 Background	Jan 2014 → Jun 2025 overdue	AIDS	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2/3	NCT00834457 Comparator	Jun 2007 → Jul 2009	Kaposi's sarcoma	Parirenyatwa Hospital	Completed	No outcome recorded
Phase 327 trials
Phase 3	NCT06630299 Comparator	Oct 2024 → Apr 2026 overdue	HIV infectious disease	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 3	NCT04155554 Comparator	Jan → Aug 2020	HIV infectious disease	University Hospital of Siena	Unknown	No outcome recorded
Phase 3	NCT03631732 Comparator	Aug 2018 → Aug 2019	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT03256422 Background	Sep 2017 → Aug 2019	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT02938520 Comparator	Oct 2016 → Aug 2018 overdue	HIV infectious disease	ViiV Healthcare	Active not recruiting	No outcome recorded
Phase 3	NCT02596334 Comparator	Dec 2015 → Jun 2017	HIV infectious disease	Centre Hospitalier Régional d'Orléans	Terminated	No outcome recorded
Phase 3	NCT02603107 Background	Nov 2015 → May 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02469246 Comparator	Jun 2015 → Dec 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02275780 Background	Dec 2014 → Sep 2016	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02157311 Background	Jul 2014 → Jan 2016	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT01605084 Background	Jun 2012 → Aug 2014	HIV infectious disease	Bristol-Myers Squibb	Withdrawn	No outcome recorded
Phase 3	NCT01363011 Background	May 2011 → Jan 2013	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01252940 Background	Nov 2010 → Jan 2012	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00928187 Comparator	Nov 2009 → Sep 2013	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT00978068 Comparator	Sep 2009 → Jan 2013	HIV infectious disease, malaria	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00727597 Background	Jul 2008 → Aug 2010	HIV infectious disease	Georgetown University	Completed	No outcome recorded
Phase 3	NCT00708162 Background	Jul 2008 → Dec 2010	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00427297 Background	Sep 2007 → May 2009	HIV infectious disease	University of Washington	Terminated	No outcome recorded
Phase 3	NCT00440947 Background	Mar 2007 → Jul 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00234091 Comparator	Apr 2006 → Sep 2011	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00085943 Background	May 2004 → ?	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00318123 Background	Apr 2004 → Apr 2007	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 3	NCT00405925 Comparator	Mar 2003 → Aug 2009	HIV infectious disease	Rijnstate Hospital	Completed	No outcome recorded
Phase 3	NCT00008554 Background	Nov 2000 → ?	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded
Phase 3	NCT00009061 Background	Nov 2000 → ?	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded
Phase 3	NCT00002409 Background	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded
Phase 3	NCT00004981 Background	—	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded

Phase 415 trials
Phase 4	NCT07138144 Comparator	Jul 2025 → Feb 2026 overdue	HIV infectious disease	José Antonio Mata Marín	Recruiting	No outcome recorded
Phase 4	NCT03447873 Comparator	Jun 2017 → Sep 2020	HIV infectious disease	Hospitales Universitarios Virgen del Rocío	Completed	No outcome recorded
Phase 4	NCT02957864 Comparator	Oct 2016 → Jun 2020	HIV infectious disease, chronic kidney disease, poisoning	Erasmus Medical Center	Unknown	No outcome recorded
Phase 4	NCT02159599 Comparator	Jul 2014 → Apr 2016	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT01637259 Comparator	Jun 2012 → Dec 2015	HIV infectious disease, proteinuria	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00865007 Comparator	Dec 2008 → Jun 2012	HIV infectious disease, lipodystrophy	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT00772902 Comparator	Oct 2008 → Sep 2009	—	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00724711 Comparator	Jul 2008 → Mar 2011	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00647244 Comparator	Jun 2008 → Aug 2010	HIV infectious disease	Aarhus University Hospital	Completed	No outcome recorded
Phase 4	NCT00544128 Comparator	Oct 2007 → Feb 2012	HIV infectious disease	International Medical Center of Japan	Completed	No outcome recorded
Phase 4	NCT02028676 Comparator	Mar 2007 → Mar 2012	HIV infectious disease	Medical Research Council	Completed	No outcome recorded
Phase 4	NCT00335270 Background	Mar 2006 → Dec 2007	HIV infectious disease	Duke University	Completed	No outcome recorded
Phase 4	NCT00192634 Comparator	Dec 2005 → Aug 2008	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00005017 Background	—	HIV infectious disease	Glaxo Wellcome	Unknown	No outcome recorded
Phase 4	NCT00386659 Background	—	HIV infectious disease	Hospital Clinic of Barcelona	Terminated	No outcome recorded

Phase not applicable2 trials
—	NCT00428116 Comparator	Sep 2007 → Jul 2013	HIV infectious disease	University of Washington	Terminated	No outcome recorded
—	NCT00051090 Background	—	HIV infectious disease, hepatitis B virus infection	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2023-09-05	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV viatris.com ↗
2018-03-05	Gilead Sciences	Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine gilead.com ↗
2005-02-28	Gilead Sciences	48-Week Data Comparing Viread Versus Abacavir as Replacement for Thymidine Analogue in Lipoatraphic HIV Patients Presented at the 12th Conference on Retroviruses and Opportunistic Infections gilead.com ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 193 sources stand behind the page.

Field	Value	Cited text
Known as	abacavir	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 176 “This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed...” NCT00085943 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir...” NCT05729568 ↗ “Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine...” NCT06602622 ↗ “NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ “Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet, will...” NCT07138144 ↗ “adult FDC of abacavir/dolutegravir/lamivudine and adult FDC of dolutegravir/lamivudine with their respective pediatric FDC formulations, taken as dispersion immediately or...” PMID 34817414 ↗ Mar 2022 “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg fixed-dose combination (FDC) tablet is currently approved in the United States (US) and Europe.” NCT02539576 ↗ “the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172” NCT02075593 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “This study aims to investigate the pharmacokinetic interactions between the TDF and the nucleosides abacavir (ABV) and lamivudine (3TC) at plasma and intracellular level.” NCT00335192 ↗ “film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine.” NCT02938520 ↗ “receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 ↗ Apr 2009 “Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection” NCT01982396 ↗ “1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily” NCT00796263 ↗ “Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.” NCT02868580 ↗ “Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription.” NCT00772902 ↗ “Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.” NCT03836833 ↗ “ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC” NCT02120352 ↗ “Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously.” NCT02028676 ↗ “Trizivir® is a combination of three antiretroviral agents: Abacavir, Lamivudine and Zidovudine in a tablet.” NCT00865475 ↗ “the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162 ↗ “Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)” NCT03602690 ↗ “300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily” NCT00270296 ↗ “once-daily combination of abacavir (ABC) + lamivudine (3TC) + EFV (referred to as EFV)” PMID 28434406 ↗ Apr 2017 “600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily” NCT02556268 ↗ “lopinavir/ritonavir plus abacavir/lamivudine versus lopinavir/ritonavir monotherapy.” PMID 23386261 ↗ Feb 2013 “nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine” NCT03256422 ↗ “containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC” NCT02105987 ↗ “Name of active ingredients:Abacavir/lamivudine/dolutegravir” NCT02509195 ↗ “Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine” NCT02246998 ↗ “remain on abacavir (600 mg) plus lamivudine (300 mg)” PMID 29475804 ↗ Feb 2018 “atazanavir 400mg + abacavir 600mg/lamivudine 300mg” NCT01102972 ↗ “dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC)” NCT06630299 ↗ “abacavir 600mg + lamivudine 300mg in one tablet QD” NCT00318123 ↗ “Epzicom (abacavir 600 mg / lamivudine 300 mg)” NCT00727597 ↗ “AZT/3TC/ABC (zidovudine/lamivudine/abacavir)” NCT00428116 ↗ “TRIUMEQ (Dolutegravir/Abacavir/Lamivudine)” NCT04827134 ↗ “in which case it will be Abacavir.” NCT00978068 ↗ “2. Abacavir 600 mg once a day” NCT02588820 ↗ “abacavir 600mgs daily” NCT01367236 ↗ “Abacavir (300 mg)” NCT01605084 ↗ “abacavir \[ABC\]” NCT04012931 ↗ “abacavir (ABC)” NCT03631732 ↗ “abacavir (ABC)” NCT06337032 ↗ “abacavir (ABC)” NCT02016924 ↗ “abacavir,” NCT02157311 ↗ “abacavir” NCT01637259 ↗ NCT00002199 ↗ NCT00002197 ↗ NCT03760458 ↗ NCT00647244 ↗ NCT00004585 ↗ NCT00000885 ↗ NCT00002409 ↗ NCT01352715 ↗ NCT00340080 ↗ NCT00004981 ↗ NCT02182765 ↗ NCT00851630 ↗ NCT00087945 ↗ NCT02957864 ↗ NCT00214890 ↗ NCT00008554 ↗ NCT00001758 ↗ NCT06658977 ↗ NCT01886638 ↗ NCT00958100 ↗ NCT00002141 ↗ NCT01220232 ↗ NCT02603107 ↗ NCT00335270 ↗ NCT00724711 ↗ NCT00002200 ↗ NCT00001119 ↗ NCT00053638 ↗ NCT00001132 ↗ NCT00314626 ↗ NCT00002205 ↗ NCT00002391 ↗ NCT00234091 ↗ NCT00078247 ↗ NCT00002389 ↗ NCT00320307 ↗ NCT00427297 ↗ NCT00002163 ↗ NCT02093585 ↗ NCT00335322 ↗ NCT00000872 ↗ NCT00086359 ↗ NCT00000912 ↗ NCT01153217 ↗ NCT02363452 ↗ NCT00000919 ↗ NCT00915655 ↗ NCT00928187 ↗ NCT00044577 ↗ NCT00192634 ↗ NCT00001766 ↗ NCT02596334 ↗ NCT00006617 ↗ NCT00000922 ↗ NCT00002198 ↗ NCT00405925 ↗ NCT00002239 ↗ NCT03360682 ↗ NCT00038506 ↗ NCT02659761 ↗ NCT00028314 ↗ NCT00006152 ↗ NCT00118898 ↗ NCT00002364 ↗ NCT02384395 ↗ NCT00009061 ↗ NCT00000865 ↗ NCT00338390 ↗ NCT00002245 ↗ NCT00002213 ↗ NCT00002216 ↗ NCT00799864 ↗ NCT00386659 ↗ NCT00647946 ↗ NCT00005017 ↗ NCT02159599 ↗ NCT04731103 ↗ NCT06428045 ↗ NCT01366547 ↗ NCT00001086 ↗ NCT00002440 ↗ NCT00002419 ↗ NCT01059422 ↗ NCT00000940 ↗ NCT00005018 ↗ NCT01656122 ↗ NCT00143702 ↗ NCT05193994 ↗ NCT00270556 ↗ NCT00046176 ↗ NCT00834457 ↗ NCT01641809 ↗ NCT00021463 ↗ NCT00337922 ↗ NCT00005106 ↗ NCT00544128 ↗ NCT00000864 ↗ NCT01146873 ↗ NCT00002183 ↗ NCT06356740 ↗ NCT00002233 ↗ NCT00002423 ↗ NCT04155554 ↗ NCT03447873 ↗ NCT01910402 ↗ NCT00006578 ↗ NCT00021489 ↗ NCT00002362 ↗ NCT00440947 ↗ NCT00244712 ↗ NCT00765271 ↗ NCT00011479 ↗ NCT00011895 ↗ NCT00192660 ↗ NCT05030025 ↗ NCT00051090 ↗ NCT00356616 ↗ NCT00031070 ↗ NCT00001968 ↗ NCT00084149 ↗ NCT00004855 ↗ NCT00002388 ↗ NCT00005764 ↗ NCT01052701 ↗ NCT00013520 ↗ NCT00002390 ↗ NCT00094367 ↗
Known as	1592U89	“A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women” NCT00000864 ↗ 6 “In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.” NCT00002217 ↗ “To assess the safety of single oral doses of 1592U89 (abacavir succinate, ABC) administered to HIV-positive individuals.” NCT00002141 ↗ “1592U89 (abacavir [ABC])” NCT00006617 ↗ “abacavir (ABC, 1592U89)” NCT00001086 ↗ “Abacavir (1592U89)” NCT00002419 ↗ “1592U89 (abacavir)” NCT00002216 ↗
Known as	abacavir succinate	“To assess the safety of single oral doses of 1592U89 (abacavir succinate, ABC) administered to HIV-positive individuals.” NCT00002141 ↗
Known as	abacavir sulfate	“The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing...” NCT02275780 ↗ 8 “Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.” PMID 19542866 ↗ Jul 2009 “ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC” NCT02120352 ↗ “abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT)” NCT00084149 ↗ “Accepted NRTIs: abacavir sulfate (ABC)” NCT00039741 ↗ NCT00102960 ↗ NCT00006154 ↗ NCT00002217 ↗ NCT00102206 ↗
Known as	Abacavir sulphate	“containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC” NCT02105987 ↗
Known as	ABC	“Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ 62 “The investigators propose to evaluate the safety of combination therapy comprising the three nucleoside analog reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT),...” NCT02363452 ↗ “The aim of this study was to investigate the effect on fasting lipid parameters of switching to tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) from abacavir (ABC)...” PMID 22910324 ↗ Aug 2012 “The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus...” NCT00005018 ↗ “the presence of low level nucleoside reverse-transcriptase inhibitor-resistant human immunodeficiency virus in subjects receiving failing first-line regimens consisting of...” PMID 19032103 ↗ Jan 2009 “bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine/abacavir (DTG/3TC/ABC), are associated with metabolic, renal, and cardiovascular adverse effects” NCT07138144 ↗ “The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg fixed-dose combination (FDC) tablet is currently approved in the United States (US) and Europe.” NCT02539576 ↗ “the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172” NCT02075593 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women” NCT00000864 ↗ “Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.” PMID 19542866 ↗ Jul 2009 “Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor (NRTI) and continues to have good efficacy even in patients who have some resistant mutations to NRTIs.” NCT01656122 ↗ “HIV-infected patients were randomized to switch from zidovudine/lamivudine (AZT/3TC) to abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC).” PMID 22479327 ↗ Mar 2012 “receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 ↗ Apr 2009 “Patients in Arm A-1 will replace the thymidine analogue component (stavudine \[d4T\] or zidovudine \[ZDV\]) of their HAART with abacavir (ABC).” NCT00028314 ↗ “The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).” NCT00086359 ↗ “Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated” PMID 20001518 ↗ Dec 2009 “The purpose of this study is to learn how safe and well-tolerated mycophenolate mofetil (MMF) is when given with abacavir (ABC).” NCT00021489 ↗ “The way abacavir (ABC) behaves in the body differs between children and adults, but little is known about ABC in adolescents.” NCT00087945 ↗ “Group 1 receives GW433908 plus abacavir (ABC) plus lamivudine (3TC); Group 2 receives nelfinavir (NFV) plus ABC plus 3TC.” NCT00008554 ↗ “To assess the safety of single oral doses of 1592U89 (abacavir succinate, ABC) administered to HIV-positive individuals.” NCT00002141 ↗ “Arm A: APV plus saquinavir soft gel capsule (SQVsgc) plus abacavir (ABC) plus efavirenz (EFV) plus adefovir (ADV).” NCT00000912 ↗ “ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC” NCT02120352 ↗ “The study-specified NRTIs will be abacavir (ABC) plus lamivudine (3TC) or didanosine (ddI) plus stavudine (d4T).” NCT00000922 ↗ “GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC)” NCT00009061 ↗ “The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV).” NCT00002239 ↗ “the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162 ↗ “Abacavir (ABC) and lamivudine (3TC) administered twice daily were compared” PMID 16280696 ↗ Dec 2005 “tenofovir (TDF) + emtricitabine (FTC) + zidovudine (ZDV) + abacavir (ABC)” NCT00335322 ↗ “Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets” NCT03760458 ↗ “containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC” NCT02105987 ↗ “Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)” NCT00440947 ↗ “abacavir (ABC)/lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV)” NCT00013520 ↗ “abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT)” NCT00084149 ↗ “The drug that will be added to a treatment is abacavir (ABC).” NCT00001132 ↗ “Regimen 3 consists of IDV, RTV, abacavir (ABC), and 3TC/ZDV.” NCT00000919 ↗ “the NRTIs emtricitabine (FTC) and abacavir sulfate (ABC)” NCT00102206 ↗ “stable regimen with DTG/abacavir (ABC)/lamivudine (3TC)” PMID 30601976 ↗ Oct 2019 “abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC)” NCT06602622 ↗ “lamivudine (3TC)/abacavir (ABC)/stavudine (d4T)” NCT00005017 ↗ “Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC)” NCT01910402 ↗ “abacavir (ABC) 600mg + lamivudine (3TC) 300mg” NCT00192634 ↗ “ABC/3TC/NVP (abacavir/lamivudine/nevirapine)” NCT00427297 ↗ “AZT/3TC/ABC (zidovudine/lamivudine/abacavir)” NCT00428116 ↗ “Accepted NRTIs: abacavir sulfate (ABC)” NCT00039741 ↗ “abacavir (ABC)-lamivudine (3TC)” PMID 21606537 ↗ Jun 2011 “abacavir (ABC)/lamivudine (3TC)” NCT00724711 ↗ “abacavir/lamivudine (ABC/3TC)” NCT02246998 ↗ “Ribavirin plus Abacavir (ABC)” NCT01052701 ↗ “drug abacavir (ABC) in blood” NCT00320307 ↗ “Arm A adds abacavir (ABC).” NCT00006152 ↗ “1592U89 (abacavir [ABC])” NCT00006617 ↗ “abacavir (ABC, 1592U89)” NCT00001086 ↗ “abacavir \[ABC\]” NCT04012931 ↗ “abacavir (ABC)” NCT06337032 ↗ “Abacavir (ABC)” NCT04731103 ↗ “abacavir (ABC)” NCT00002419 ↗ “abacavir (ABC)” NCT02016924 ↗ “abacavir (ABC)” NCT03631732 ↗ “abacavir (ABC)” NCT00002362 ↗ “Abacavir (ABC)” NCT01146873 ↗ “abacavir (ABC)” NCT00002245 ↗ NCT01127204 ↗
Known as	ABC: abacavir: Ziagen	“ABC: abacavir: Ziagen” NCT02028676 ↗
Known as	Ziagen	“Ziagen (Abacavir) 300mg BID” NCT00004585 ↗
Action	Inhibit	“HIV nucleoside reverse transcriptase inhibitors (NRTI)” PMID 16103764 ↗ Sep 2005
Modality	Other / unclassified	“dual nucleosides” NCT00000919 ↗
Route	Oral	“abacavir 300 mg po BID” NCT00001766 ↗